Nafliva™

"The global Non-Alcoholic Steatohepatitis (NASH) market is expected to reach $ 13.38 Billion by 2026". According to a new report by Reports and Data, Feb. 27, 2019 (GLOBE NEWSWIRE).
Based on the American Liver Foundation: " Non-Alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of the population in the United States", and currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of NASH patients suffer from either obesity or diabetes. When fat buildup occurs, it puts people at risk of developing Non-Alcoholic Fatty Liver Disease (NAFLD).

What is Non-Alcoholic Fatty Liver Disease (NAFLD)?
NAFLD is the buildup of extra fat in the liver cells that is not caused by excessive alcohol usage. It is normal for the liver to contain some fat, however, if more than 5% – 10% percent of the liver’s weight is fat, then it is considered to be fatty liver disease (Steatosis).
Stage I
Simple Fatty Liver (Steatosis) 
Stage II
Non-Alcoholic Steatohepatitis (NASH)
Stage III
Fibrosis
Stage IV
Cirrhosis
A buildup of excess fat in the liver that generally does not have severe consequences.
Inflammation starts to take place, and the patient is at risk of more serious outcomes.
Consistent inflammation causes scar tissues to form around the liver’s blood vessels.
The liver shrinks, scars, and becomes lumpy, which results in putting the patient at risk of total liver failure.

What Are the Effects Of NAFLD?
The early stages of Non-Alcoholic Fatty Liver Disease usually don’t cause much harm. Unfortunately, these issues can develop into life-threatening situations. Some of the most concerning situations are an increased risk of diabetes, liver failure, and kidney disease. Most people with NAFLD won't develop any serious problems, but if you're diagnosed with the condition it's a good idea to take the steps necessary to prevent it from getting worse.